Results 91 to 100 of about 15,373 (177)

The use of fulvestrant, a parenteral endocrine agent, in intestinal obstruction due to metastatic lobular breast carcinoma

World Journal of Surgical Oncology, 2008
Background The role of fulvestrant in the management of intestinal obstruction associated with lobular carcinoma has not been specifically described.
Rampaul Rajendra Singh, Tang Jasmine YM, Cheung Kwok L   +2 more
doaj   +1 more source

Efficacy and Safety of Intraventricular Thiotepa in Combination With Methotrexate for Leptomeningeal Metastasis From Breast Cancer (NJMU‐BC04): A Single‐Arm Phase II Study

MedComm, Volume 7, Issue 9, September 2026.
Leptomeningeal metastasis (LM), an uncommon yet highly fatal condition, involves malignant tumor infiltration of the meninges resulting in progressive neurological deterioration and severe quality‐of‐life impairment. LM remains largely refractory to treatment and lacks standardized treatment consensus, with a low intracranial objective response rate ...
Wenbin Zhou, Mengyao Zha, Hehui Fang, Kai Cao, Jiaqi Yong, Yue Sun, Yuan Yuan, Jian Zhang, Shencun Fang, Qiang Ding, Wei Li   +10 more
wiley   +1 more source

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

Signal Transduction and Targeted Therapy
CDK2 is a principal mediator of CDK4/6 resistance. Concurrent CDK2/4/6 blockade may be effective in treating HR-positive, HER2-negative advanced breast cancer (ABC).
Yongmei Yin, Qingyuan Zhang, Tao Sun, Chunfang Hao, Zhihong Wang, Jin Yang, Yongsheng Wang, Yanxia Shi, Jing Sun, Quchang Ouyang, Haichuan Su, Jinsheng Wu, Lu Gan, Meng Han, Liming Gao, Xiaojia Wang, Bing Zhao, Hui Li, Jiuda Zhao, Hongwei Yang, Fangling Ning, Fuguo Tian, Juliang Zhang, Hongmei Sun, Zhaofeng Niu, Hong Zong, Aimin Zang, Xinshuai Wang, Xinyu Qian, Shikai Wu, Jianyun Nie, Lijia He, Ying Cheng, Yanrong Hao, Yi Zhai, Huiping Li, Jingfen Wang, Shihong Wei, Man Li, Yunjiang Liu, Hongqiang Guo, Qun Hu, Lina Liu, Xinghua Han, Ruizhen Luo, Mingli Ni, Xianjun Tang, Zhenhua Zhai, Meiqian Ding, Haibo Wang, Peng Shen, Xian Wang, Lian Liu, Wenyan Chen, Gang Liu, Zhengwen Cai, Zefei Jiang   +56 more
doaj   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source

Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: A Phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Ini

, 2015
BACKGROUND: The median survival for women with hormone-receptor-positive (HR+) stage IV metastatic breast cancer (MBC) is 36 months. Strategies to improve outcome for postmenopausal women, include combinations of aromatase inhibitors (AIs) with either ...
Gralow, Julie, Daniel Hayes, Lew, Danika, Hayes, Daniel, Tripathy, Debu, Peter Kuhn, Julie Gralow, Moore, Halle, Debu Tripathy, Halle Moore, Kuhn, Peter, Hicks, James, Danika Lew, Schott, Anne, George Somlo, William Barlow, Gabriel Hortobagyl, James Hicks, Barlow, William, Hortobagyl, Gabriel, Somlo, George, Anne Schott   +21 more
core   +1 more source

Fulvestrant in the treatment of luminal metastatic breast cancer: The balance of effectiveness and safety

, 2021
The review presents the results of studies of fulvestrant in metastatic breast cancer (MBC). Hormone therapy is an effective method of treating hormone-positive metastatic breast cancer even in the presence of visceral metastases in the absence of a ...
Koroleva I.A.
core  

Fulvestrant and male breast cancer: a pooled analysis

, 2015
Male breast cancer is an uncommon malignancy; little is known regarding hormonal manipulations for tamoxifen-resistant male breast cancer patients. This is the first pooled analysis of the literature to synthesize all available data and to evaluate the ...
Chrysikos, D., Sergentanis, T.N., Dimopoulos, M.-A., Psaltopoulou, T., Zagouri, F.   +4 more
core   +1 more source

Advances of fulvestrant in treatment of advanced breast cancer in hormone receptor-positive postmenopausal women

Zhongguo aizheng zazhi, 2016
Endocrine therapy targeting estrogen pathway is one of the first-line treatment choices of advanced breast cancer. Fulvestrant is a pure estrogen antagonist that blocks and downgrades estrogen receptor, which makes it effective in the treatment of ...
王佳玉, 徐兵河
doaj  

Abstract P4-04-17: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model

, 2018
Background: Breast cancer is subdivided into categories based on tumor receptor status, with estrogen-receptor positive (ER+) breast cancer making up approximately two-thirds of all breast cancers diagnosed.
F Garner, T Bihani, H Arlt
core   +1 more source

Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer

Therapeutic Advances in Medical Oncology
The landscape of breast cancer treatment continues to evolve. Survival rates have improved due to advancements in treatments such as endocrine therapy, cyclin-dependent kinase 4/6 inhibitors and targeted therapies.
Karam Aboud, Magda Meissner, Rob Jones
doaj   +1 more source